02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 4.12.4 continued<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Tobias-<br />

Machado<br />

2003<br />

[29]<br />

Brazil<br />

Controlled<br />

trial<br />

Transrectal core prostate<br />

biopsy. No risk factors<br />

(catheter, pos urine culture,<br />

diabetes, valvular<br />

disease). No ab 1 week<br />

prior to procedure.<br />

n=257<br />

I1: Single dose ciprofloxacin<br />

500 mg po 2 h prior to<br />

biopsy (n=64)<br />

I2: Ciprofloxacin 500 mg<br />

po x 2 for 3 days (n=46)<br />

C1: Chloramphenicol<br />

500 mg<br />

po x 2 for 3 days<br />

(n=71)<br />

C2: Norfloxacin<br />

400 mg po x 2<br />

for 3 days (n=76)<br />

Minor infectious complications<br />

I1: 2/64 (3.1%)<br />

I2: 1/46 (2.1%)<br />

C1: 12/71 (16.9%)<br />

C2: 8/76 (10.5%)<br />

Major infectious complication<br />

Prostatitis with septis<br />

I1: 0<br />

I2: 0<br />

C1: 1/71 (1.4%)<br />

C2: 0<br />

I1, I2 vs C1, C2 sign<br />

I1 vs I2 ns<br />

Not<br />

indicated<br />

Moderate<br />

Minor infectious<br />

complications =<br />

UTI, self-limited<br />

fever, prostatitis,<br />

epididymitis<br />

Yamamoto<br />

2008<br />

[30]<br />

Japan<br />

RCT<br />

Transrectal core prostate<br />

biopsy. Sterile urine and<br />

no risk factors identified<br />

before biopsy<br />

I: Tosufloxacin 300 mg<br />

x 2 for 2 days. First dose 2 h<br />

before biopsy (n=124)<br />

C: Levofloxacin<br />

200 mg x 2 for<br />

2 days, same<br />

regimen (n=119)<br />

Prostatitis/cystitis<br />

I: 6/124 (4.8%)<br />

C: 6/119 (5.0%)<br />

ns<br />

Not<br />

reported<br />

Moderate<br />

Rather high rates<br />

for low-risk patients<br />

Hospitalisation<br />

I: 3/124 (2.4%)<br />

C: 3/119 (2.5%)<br />

ns<br />

ab = Antibiotics; ABP = Antibiotic prophylaxis; C = Control group; cfu = Colony forming<br />

units; h = Hour; I = Intervention group; im = Intramuscular; ITT = Intention-to-treat;<br />

iv = Intravenous; n = Number of patients; NNT = Number needed to treat; ns= Non<br />

significant; po = Per os; PP = Per protocol; RCT = Randomised controlled trial; RF =<br />

Rheumatoid factors; RR = Relative risk; sign = Significant; TMP/SMX = Trimethoprim/<br />

Sulfamethoxazole; TPB = Transrectal prostatic biopsy; UTI = Urinary tract infection;<br />

VHD = Valvular heart disease<br />

462 antibiotikaprofylax <strong>vid</strong> <strong>kirurgiska</strong> <strong>ingrepp</strong> KAPITEL 4 • den systematiska litteraturöversikten<br />

463

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!